Planta Med 2006; 72(8): 761-763
DOI: 10.1055/s-2006-931600
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of the Anti-Trypanosomal Activity of Tyropeptin A

Dietmar Steverding1 , 2 , Alexander J. Pemberton3 , Howard Royle2 , Robert W. Spackman2 , A. Jennifer Rivett3
  • 1Biomedical Research Centre, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
  • 2School of Biological Sciences, University of Bristol, Bristol, UK
  • 3Department of Biochemistry, School of Medical Sciences, University of Bristol, Bristol, UK
Further Information

Publication History

Received: December 1, 2005

Accepted: March 5, 2006

Publication Date:
29 May 2006 (online)

Abstract

The natural compound tyropeptin A, a new peptidyl aldehyde proteasome inhibitor, was tested for its trypanocidal activity in vitro using culture-adapted bloodstream forms of Trypanosoma brucei. The concentrations of tyropeptin A required to reduce the growth rate by 50 % and to kill all cells were 10 and 100 times lower for bloodstream-form trypanosomes than for human leukaemia HL-60 cells, respectively. Enzymatic analysis showed that the trypsin-like activity of the trypanosome proteasome and the chymotrypsin-like activity of the mammalian proteasome are particularly sensitive to inhibition by tyropeptin A. The results suggest that natural compounds targeting the trypsin-like activity of the proteasome may serve as leads for rational drug development of novel anti-trypanosomal agents.

References

  • 1 Barrett M P, Burchmore R J, Stich A, Lazzari J O, Frasch A C, Cazzulo J J. et al . The trypanosomaises.  Lancet. 2003;  362 1469-80
  • 2 Fairlamb A H. Chemotherapy of human African trypanosomiasis: current and future prospects.  Trends Parasitol. 2003;  19 488-94
  • 3 Matovu E, Seebeck T, Enyaru J CK, Kaminsky R. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle.  Microbes Infect. 2001;  3 763-70
  • 4 Hoet S, Opperdoes F, Brun R, Quetin-Leclercq J. Natural products active against African trypanosomes: a step towards new drugs.  Nat Prod Rep. 2004;  21 353-64
  • 5 Nkemgu-Njinkeng J, Rosenkranz V, Wink M, Steverding D. Antitrypanosomal activities of proteasome inhibitors.  Antimicrob Agents Chemother. 2002;  46 2038-40
  • 6 Glenn R J, Pemberton A J, Royle H J, Spackman R W, Smith E, Rivett A J. et al . Trypanocidal effect of α′,β′-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity.  Int J Antimicrob Agents. 2004;  24 286-9
  • 7 Momose I, Sekizawa R, Hashizume H, Kinoshita N, Homma Y, Hamada M. et al . Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK933-dF2. 1. Taxonomy, isolation, physio-chemical properties and biological activities.  J Antibiot (Tokyo). 2001;  54 997-1003
  • 8 Scory S, Steverding D. Differential toxicity of ricin and diphtheria toxin for bloodstream forms of Trypanosoma brucei .  Mol Biochem Parasitol. 1997;  90 289-95
  • 9 Scory S, Caffrey C R, Stierhof Y D, Ruppel A, Steverding D. Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-Phe-Ala-CHN2 .  Exp Parasitol. 1999;  91 327-33
  • 10 Steverding D, Stierhof Y D, Fuchs H, Tauber R, Overath P. Transferrin-binding protein complex is the receptor for transferrin uptake in Trypanosoma brucei .  J Cell Biol. 1995;  131 1173-82
  • 11 Kabiri M, Steverding D. Trypanosoma evansi: demonstration of a transferrin receptor derived from expression site-associated genes 6 and 7.  J Parasitol. 2001;  87 1189-91
  • 12 Steverding D, Spackman R W, Royle H J, Glenn R J. Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors.  Parasitol Res. 2005;  95 73-6
  • 13 Hua S B, To W Y, Nguyen T T, Wong M L, Wang C C. Purification and characterization of proteasomes from Trypanosoma brucei .  Mol Biochem Parasitol. 1996;  78 33-46
  • 14 Wang C C, Bozdech Z, Liu C L, Shipway A, Backes B J, Harris J L. et al . Biochemical analysis of the 20S proteasome of Trypanosoma brucei .  J Biol Chem. 2002;  278 15 800-8
  • 15 Merschjohann K, Sporer F, Steverding D, Wink M. In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense .  Planta Med. 2001;  67 623-7
  • 16 Hirumi H, Hirumi K, Doyle J J, Cross G AM. In vitro cloning of animal-infective bloodstream forms of Trypanosoma brucei .  Parasitology. 1980;  80 371-82
  • 17 Collins S R, Gallo R C, Gallagher R E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension cultures.  Nature. 1997;  270 347-9
  • 18 Baltz T, Baltz D, Giroud C, Crockett J. Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense .  EMBO J. 1985;  4 1273-7
  • 19 Huber W, Koella J C. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites.  Acta Trop. 1993;  55 257-61
  • 20 Rivett A J, Savory P J, Djaballah H. Multicatalytic endopeptidase complex: proteasome.  Methods Enzymol. 1994;  244 331-50

Priv.-Doz. Dr. Dietmar Steverding

School of Medicine, Health Policy and Practice

University of East Anglia

Norwich NR4 7TJ

United Kingdom

Fax: +44-1603-59-3752

Email: dsteverding@hotmail.com